|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also report in lung cancer the GOPC-ROS1 fusion originally discovered and characterized in a glioma cell line.
|
23052255 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
|
27179848 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) NUT carcinoma.
|
29538329 |
2018 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
|
27068398 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1.
|
25667280 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, the overall survival of the 13 ROS1-positive patients with lung cancer from initiation of pemetrexed-based chemotherapy was significantly prolonged when compared with that of 169 pemetrexed-treated patients with EGFR/anaplastic lymphoma kinase/ROS1-negative adenocarcinoma (p = 0.01).
|
27575422 |
2017 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
|
31562206 |
2020 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
|
28181564 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
|
26673800 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, the use of crizotinib in ROS1-rearranged lung cancer exhibits significant clinical efficacy.
|
28538401 |
2017 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have used human lung cancer cell lines carrying a plasmid vector containing a (CA)(13) microsatellite sequence to study frameshift mutations mediated by ROS-generating chemicals paraquat and hydrogen peroxide.
|
10910953 |
2000 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EML4-ALK inversion and ROS1 fusions emerge as common fusion abnormalities in IMT, closely recapitulating the pattern seen in lung cancer.
|
25723109 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
|
28743163 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The WNK1-ROS1 rearrangement appeared to be a novel driver of the lung cancer.
|
30797499 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to the lung cancer-related genes (TP53, EGFR, KRAS, PIK3CA, and ROS1), this study revealed "novel" genes not previously implicated in NSCLC.
|
22696596 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The molecular target drugs for lung cancer with anaplastic lymphoma kinase (ALK) gene translocation (the fusion gene, EML4-ALK) was approved, and those targeting lung cancers addicted ROS1, RET, and HER2 have been under development.
|
27686809 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data confirmed that CG caused apoptosis through the activation of extrinsic and intrinsic pathways, cell cycle arrest, and ROS generation in A549 and NCI-H1299 lung cancer cells.
|
31215445 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer.
|
31572036 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR, ALK, and ROS1 are 3 major driver genes that play an important role in lung cancer development and precision management.
|
30653139 |
2019 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1-2%) of patients with non-small cell lung cancer (NSCLC).
|
31382924 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)-rearranged lung cancer is rare and comprises only 1% of lung adenocarcinoma cases.
|
30655791 |
2019 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Crizotinib was the first tyrosine kinase inhibitor to demonstrate activity in ROS1-rearranged lung cancer, and remains the recommended first-line therapy for patients with advanced ROS1-rearranged non-small cell lung cancer.
|
31313100 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to compare two recent amplicon-based RNA-sequencing techniques: FusionPlex<sup>®</sup> Alk Ret Ros1 v2 Kit (Archer<sup>®</sup> ) with FHS-003Z-12-Human Lung Cancer Panel (Qiagen<sup>®</sup> ) and assessed the accuracy of the data for therapy management.
|
31651105 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are 'must-test' biomarkers in the molecular diagnostics of advanced-stage lung cancer patients.
|
31726498 |
2019 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The identification of the location of the rs9387478 single nucleotide polymorphism in the genomic interval containing the DCBLD1 and ROS1 genes, together with the finding that the rs9387478 polymorphism correlates with EGFR mutation status, may have important implications for therapeutic approaches targeting EGFR or ROS1 in patients with lung cancer.
|
26689248 |
2016 |